Structural neuroimaging in psychosis: A systematic review and economic evaluation

Health Technology Assessment

Volumn 12, Issue 18, 2008, Pages

  Albon, E ^a   Tsourapas, A ^a   Frew, E ^a   Davenport, C ^a   Oyebode, F ^b   Bayliss, S ^a   Arvanitis, T ^a   Meads, C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CONTRAST MEDIUM; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE;

ADULT; AGRANULOCYTOSIS; BOLUS INJECTION; BRAIN CYST; BRAIN TUMOR; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ELECTROCONVULSIVE THERAPY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HISTORY OF MEDICINE; HUMAN; IMAGE ANALYSIS; INCIDENTAL FINDING; INFORMATION RETRIEVAL; INTERMETHOD COMPARISON; MYOCARDITIS; NATIONAL HEALTH SERVICE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREDICTION; PRETEST POSTTEST DESIGN; PREVALENCE; PSYCHOSIS; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 47249162940     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12180     Document Type: Review

References (157)

1. Sims A. Symptoms in the mind. 3rd ed. London: Saunders; 2003.
2. Boeing L, Murray V, Pelosi A, McCabe R, Blackwood D, Wrate R. Adolescent-onset psychosis: prevalence, needs and service provision. Br J Psychiatry 2007;190:18-26.
3. Forstl H, Besthorn C, Geiger-Kabisch C, Sattel H, Schreiter-Gasser U. Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings. Acta Psychiatr Scand 1993;87:395-9.
4. WHO. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1993.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
6. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Arch Gen Psychiatry 2005; 62:975-83.
7. DeLisi LE, Zipursky RB, Kapar S. Structural brain changes in schizophrenia. Arch Gen Psychiatry 1999;56:195-6.
8. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M, et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60:585-94.
9. MacDonald AW III, Carter CS, Kerns JG, Ursu S, Barch DM, Holmes AJ, et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am J Psychiatry 2005;162:475-84.
10. Farrow TF, Whifford TJ, Williams LM, Gomes L, Harris AW. Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder. Biol Psychiatry 2005;58:713-23.
11. O'Brien M, Singleton N, Sparks J, Meltzer H, Brugha T. Adults with a psychotic disorder living in private households, 2000. London: HMSO National Statistics; 2002.
12. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003;122:69-87.
13. Bebbington PE, Bhugra D, Brugha T, Singleton N, Farrell M, Jenkins R, et al. Psychosis, victimisation and childhood disadvantage. Br J Psychiatry 2004; 185:220-6.
14. Wooley J, McGuire P. Neuroimaging in schizophrenia: what does it tell the clinician? Adv Psychiatr Treat 2005; 11:195-202.
15. Edwards J, McGorry P. Implementing early interventions in psychosis: a guide to establishing early psychosis services. London: Martin Dunitz; 2002.
16. Graham P, Turk J, Verhulst F. Child psychiatry, a developmental approach. Oxford: Oxford University Press; 1999.
17. Fladby T, Schuster M, Gronli O, Sjoholm H, Loseth S, Sexton H, et al. Organic brain disease in psychogeriatric patients: impact of symptoms and screening methods on the diagnostic process. J Geriatr Psychiatry Neurol 1999;12:16-20.
18. Castle DJ. Gender and age at onset in schizophrenia. Late onset schizophrenia. Petersfield: Wrightson Biomedical Publishing; 1999.
19. Lisanby SH, Kohler C, Swanson CL, Gur RE. Psychosis secondary to brain tumor. Semin Clin Neuropsychiatry 1998;3:12-22.
20. Purdie FR, Honigman B, Rosen P. Acute organic brain syndrome: a review of 100 cases. Ann Emerg Med 1981;10:455-61.
21. Falkai P. Differential diagnosis in acute psychotic episode. Int Clin Psychopharmacol 1996; 11 Suppl 2:13-17.
22. Mintzer J, Targum SD. Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol 2003; 16:199-206.
23. Tucker GJ, Price TRP, Johnson VB, AcAllister T. Phenomenology of temporal lobe dysfunction: a link to atypical psychosis - a series of cases. J Nerv Ment Dis 1986;174:348-56.
24. Jablensky A. Course and outcome of schizophrenia and their prediction. In Gelder MG, Lopez-Ibor JJ Jr, Andreason NC, editors. New Oxford textbook of psychiatry. Oxford: Oxford University Press; 2000.
25. Riecher-Rossler A, Hafner H, Munk-Jorgensen P. Validity of late onset schizophrenia: a European view. In Howard R, Rabins PV, Castle DJ, editors. Late onset schizophrenia. Petersfield and Philadelphia: Wrightson Biomedical Publishing; 1999.
26. Stirling J, White C, Lewis S, Hopkins R, Tantam D, Huddy A, et al. Neurocognitive function and outcome in first-episode schizophrenia: a ten-year follow-up of an epidemiological cohort. Schizophr Res 2003;65:75-86.
27. Jolly D, Kosky N, Holloway F. Caring for people who enter old age with an enduring or relapsing mental illness ('graduates'). Council Report CR110. London: Royal College of Psychiatrists; 2002.
28. Lerav I, Ponizovsky A, Grinshpoon A. Cancer and schizophrenia. Br J Psychiatry 2006;188:191.
29. British Medical Association/Royal Pharmaceutical Society of Great Britain. British National Formulary. Vol. 52. London: BMA and RPSGB; 2006.
30. Killackey E, Yung AR. Effectiveness of early intervention in psychosis. Curr Opin Psychiatry 2007;20:121-5.
31. Emsley R, Rabinowitz J, Medori R, Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors and clinical and functional outcome correlates. Schizophr Res 2007; 89:129-39.
32. Wing JK. Severe mental illness. In Stevens A, Raftery J, Mant J, Simpson S, editors. Health care needs assessment. Oxford: Radcliffe Publishing; 2004.
33. Brewin J, Cantwell R, Dalkin T, Fox R, Medley I, Glazebrook C, et al. Incidence of schizophrenia in Nottingham. Br J Psychiatry 1997;171:140-4.
34. King M, Coker E, Leavey G, Hoare A, Johnson-Sabine E. Incidence of psychotic illness in London: comparison of ethnic groups. BMJ 1994;309:1115-19.
35. Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, et al. Epidemiology of first episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years. Schizophr Bull 2005;31:624-38.
36. Wiles NJ, Zammit S, Bebbington PE, Singleton N, Meltzer H, Lewis G. Self-reported psychotic symptoms in the general population. Br J Psychiatry 2006;188:519-26.
37. NHS. Hospital episode statistics online. URL: http://www.hesonline.nhs.uk. Accessed April 2007
38. Jenkins R, Lewis G, Bebbington PE, Brugha T, Farrell M, Gill B, et al. The national psychiatric morbidity surveys of Great Britain - initial findings from the household survey. Psychol Med 1997; 27:775-89.
39. Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric morbidity among adults living in private households, 2000. London: HSMO National Statistics; 2001.
40. Bhugra D, Leff J, Mallett R, Der G, Corridan B, Rudge S. Incidence and outcome of schizophrenia in Whites, African-Caribbeans and Asians in London. Psychol Med 1997;27:791-8.
41. Brugha T, Jenkins R, Bebbington PE, Meltzer H, Lewis G, Farrell M. Risk factors and the prevalence of neurosis and psychosis in ethnic groups in Great Britain. Soc Psychiatry Psychiatr Epidemiol 2004; 39:939-46.
42. Goldeacre M, Duncan M, Cook-Mozaffari P, Davidson M, McGuinness H, et al. Schizophrenia in England 1996 to 2004 mortality trends. Oxford: South East England Public Health Observatory and Oxford University; 2006.
43. Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards G, et al. Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. Br J Psychiatry 2006; 188:223-8.
44. Spencer E, Birchwood M, McGovern D. Management of first-episode psychosis. Adv Psychiatr Treat 2001;7:133-42.
45. Singh SP, Grange T. Measuring pathways to care in first-episode psychosis: a systematic review. Schizophr Res 2006; 81:75-82.
46. Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A. The Australian national survey of psychotic disorder: profile of psychosocial disability and its risk factors. Psychol Med 2002; 32:639-47.
47. Melle I, Friis S, Haahr U, Johannesen JO, Larsen TK, Opjordsmoen S, et al. Measuring quality of life in first episode psychosis. Eur Psychiatry 2005;20:474-83.
48. Malla AK, Noman RM, McLean TS, MacDonald C, McIntosh E, Dean-Lashley F, et al. Determinants of quality of life in first episode psychosis. Acta Psychiatr Scand 2004;109:46-54.
49. Browne S, Clarke M, Gervin M, Waddington JL, Larkin C, O'Callaghan E. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000;176:173-6.
50. Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction. Br J Psychiatry 2006; 188:37-45.
51. Sim K, Mahendran R, Chong SA. Health-related quality of life and psychiatric comorbidity in first episode psychosis. Compr Psychiatry 2005;46: 278-83.
52. Awad AG, Voruganti LN, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997; 11:32-47.
53. O'Toole MS, Ohlsen RI, Taylor TM, Purvis R, Walters J, Pilowsky LS. Treating first episode psychosis - service users' perspective: a focus group evaluation. J Psychiatr Mental Health Nurs 2004; 11:319-26.
54. Bertolote J, McGorry P, on behalf of WHO and IEPA. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry 2005;187 (Suppl 48):s116-19.
55. Singh SP, Fisher HL. Early intervention in psychosis:obstacles and opportunities. Adv Psychiatr Treat 2005;11:71-8.
56. Tait L, Lester H, Birchwood M, Freemantle N, Wilson S. Design of the BiRmingham Early Detection In untREated psyChosis Trial (REDIRECT): cluster randomised controlled trial of general practitioner education in detection of first episode psychosis. BMC Health Serv Res 2005; 5(19).
57. Ananth J, Gamal R, Miller M, Wohl M, Vandewater S. Is the routine CT head scan justified for psychiatric patients? A prospective study. J Psychiatry Neurosci 1993;18:69-73.
58. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Arlington, VA: American Psychiatric Publishing; 2004.
59. Green GC. Guidelines for assessing and diagnosing acute psychosis: a primer. J Am Psychiatr Nuts Assoc 2002;S31-5.
60. National Collaborating Centre for Mental Health. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary. care. Clinical Guideline 1. London: NICE; 2002.
61. Haddock G, Lewis S, Bentall R, Dunn G, Drake R, Tarrier N. Influence of age on outcome of psychological treatments in first-episode psychosis. Br J Psychiatry 2006;188:250-4.
62. Barnes TR, Davison S, Ferrier IN, Howard R, Kerwin R, King DJ, et al. Consensus statement on high-dose antipsychotic medication. Council Report CR138. London: Royal College of Psychiatrists; 2005.
63. Thornley B, Rathbone J, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2003; Issue 2.
64. NICE. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guideline 38. London: NICE; 2006.
65. Pinfold V, Smith J, Shiers D. Audit of early intervention in psychosis service development in England in 2005. Psychiatr Bull 2007; 31:7-10.
66. Smith J, Shiers D, Purdy R. UK early intervention community-an update on a growing social movement delivering better life outcomes for young people. London: Department of Health; 2006.
67. Webb S. The physics of medical imaging. Bristol: Institute of Physics Publishing; 1988.
68. Brant WE, Helms CA. Fundamentals of diagnostic radiology. Philadelphia, PA: Lippincott, Williams and Wilkins; 2007.
69. Berman KF, Weinberger DR. Neuroradiology in psychiatry. Psychiatr Clin North Am 1984;7:487-501.
70. Katayama H, Ymamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990;175: 621-8.
71. Magnetic resonance imaging. URL: http://en.wikipaedia.org/wiki/ Mri. Accessed 4 May 2007.
72. Henkelman RM, Broskill MJ. Artifacts in magnetic resonance imaging. Rev Magn Reson Med 1987;2: 1-126.
73. Melendez JC, McCrank E. Anxiety-related reactions associated with magnetic resonance imaging examinations. JAMA 1993; 270:745-7.
74. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA 1999;281:36-9.
75. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157:16-25.
76. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005;162:2233-45.
77. Elkis H, Friedman L, Wise A, Meltzer HY. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch Gen Psychiatry 1995;52: 735-46.
78. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006; 188:510-18.
79. Burnett R, Mallett R, Bhugra D, Hutchinson G. The first contact of patients with schizophrenia with psychiatric services: social factors and pathways to care in a multi-ethnic population. Psychol Med 1999;29:475-83.
80. Skeate A, Jackson C, Jones C. Duration of untreated psychosis and pathways to care in first-episode psychosis. Br J Psychiatry 2002; 181:s73-7.
81. Office for National Statistics. NHS reference costs 2005-06, mental health services: inpatient data, MHIPA2 adult: acute care. London: Office for National Statistics; 2007.
82. Knottnerus JA, Dinant G-J, van Schayck OP. The diagnostic before-after study to assess clinical impact. In Knottnerus JA, editor. The evidence base of clinical diagnosis. London: BMJ Books; 2002. pp. 81-94.
83. Guyatt GH, Tugwell PX, Feeny DH, Drummond MF, Haynes RB. The role of before-after studies of therapeutic impact in the evaluation of diagnostic technologies. J Chron Dis 1986;39:295-304.
84. Whiting P, Rutjes AWDJ, Reitsma JB, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8(25).
85. Adams M, Kutcher S, Antoniw E, Bird D. Diagnostic utility of endocrine and neuroimaging screening tests in first-onset adolescent psychosis. J Am Acad Child Adolesc Psychiatry 1996;35:67-73.
86. Agzarian MJ, Chryssidis S, Davies RP, Pozza CH. Use of routine computed tomography brain scanning of psychiatry patients. Australas Radiol 2006;50:27-8.
87. Ananth J, Miller M, Vandewater S, Brodsky A, Gamal R, Wohl M. Physical illness in hospitalized psychiatric patients. Ann Clin Psychiatry 1992;4: 99-104.
88. Bain BK. CT scans of first-break psychotic patients in good general health. Psychiatr Serv 1998;49: 234-5.
89. Battaglia J, Spector IC. Utility of the CAT scan in a first psychotic episode. Gen Hosp Psychiatry 1988; 10:398-401.
90. Borgwardt SJ, Radue EW, Gotz K, Aston J, Drewe M, Gschwandtner U, et al. Radiological findings in individuals at high risk of psychosis. J Neurol Neurosurg Psychiatry 2006;77:229-33.
91. Colohan H, O'Callaghan E, Larkin C, Waddington JL. An evaluation of cranial CT scanning in clinical psychiatry. Ir J Med Sci 1989; 158:178-81.
92. Emsley RA, Stander D, Bell PSH, Gledhill RF. Computed tomography in psychiatric patients. S Afr Med J 1986;70:212-14.
93. Evans NJR. Cranial computerized tomography in a clinical psychiatry: 100 consecutive cases. Compr Psychiatry 1982;23:445-50.
94. Gewirtz G, Squires-Wheeler E, Sharif Z, Honer WG. Results of computerised tomography during first admission for psychosis. Br J Psychiatry 1994; 164:789-95.
95. Jeenah FY, Moosa MYT. CT scans in psychiatric patients - an exploratory study at Chris Hani Baragwanath Hospital. S Afr J Psychiatry 2007; 13:22-5.
96. Larson EB, Mack LA, Watts B, Cromwell LD. Computed tomography in patients with psychiatric illnesses: advantage of a "rule in" approach. Ann Intern Med 1981;95:360-4.
97. Lesser IM, Miller BL, Boone KB, Hill-Gutierrez E, Mehringer CM, Wong K, et al. Brain injury and cognitive function in late-onset psychotic depression. J Neuropsychiatry Clin Neurosci 1991; 3:33-40.
98. Lesser IM, Jeste DV, Boone KB, Harris MJ, Miller BL, Hill-Gutierrez E. Late-onset psychotic disorder, not otherwise specified: clinical and neuroimaging findings. Biol Psychiatry 1992; 31:419-23.
99. Lubman DI, Velakoulis D, McGorry PD, Smith DJ, Brewer W, Stuart G, et al. Incidental radiological findings on brain magnetic resonance imaging in first-episode psychosis and chronic schizophrenia. Acta Psychiatr Scand 2002;106:331-6.
100. McClellan RL, Eisenberg RL, Giyanani VL. Routine CT screening of psychiatry inpatients. Radiology 1988;169:99-100.
101. McKay D, Gorrell J, Cornish A, Tennant C, Rosen A, Moss B, et al. Let's get physical: an audit of medical practice in first episode psychosis. Australas Psychiatry 2006;14:146-9.
102. Miller BL, Lesser IM, Boone KB, Hill E, Mehringer CM, Wong K. Brain lesions and cognitive function in late-life psychosis. Br J Psychiatry 1991;158:76-82.
103. Roberts JKA, Lishman WA. The use of the CAT head scanner in clinical psychiatry. Br J Psychiatry 1984;145:152-8.
104. Schemmer DS, Siekierski M, Steiner M. CT of the brain: how useful is it in general psychiatry? Can J Psychiatry 1999;44:929.
105. Wahlund LO, Agartz I, Saaf J, Wetterberg L, Marions O. MRI in psychiatry: 731 cases. Psychiatry Res 1992;45:139-40.
106. Cunningham-Owens DG, Johnstone EC, Bydder GM, Kreel L. Unsuspected organic disease in chronic schizophrenia demonstrated by computed tomography. J Neurol Neurosurg Psychiatry 1980;43:1065-9.
107. Vavilov SB, Belova OG, Nikiforchuk NM, Savvateeva YN, Atyasova EV, Baev AA. Computer-aided tomography (CT) in diagnosis of organic brain lesions in schizophrenics. Vestn Rentgenol Radiol 1993;68(3):43-8 (in Russian).
108. Forstl H. Psychiatric, neurological and medical aspects of misidentification syndromes: a review of 260 cases. Psychol Med 1991;21:905-10.
109. Mooney C, Mushlin AI, Phelps CE. Targeting assessments of magnetic resonance imaging in suspected multiple sclerosis. Med Decis Making 1990;10:77-94.
110. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Operational Research 1982;30:1043-69.
111. Simon DG, Lubin MF. Cost-effectiveness of computerized tomography and magnetic resonance imaging in dementia. Med Decis Making 1985; 5:335-54.
112. McMahon PM, Araki S, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiol 2000;217:58-68,
113. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-45.
114. Evens RG, Jost RG. The clinical efficacy and cost analysis of cranial computed tomography and the radionuclide brain scan. Semin Nucl Med 1977; 7:129-36.
115. Szczepura AK, Fletcher J, Fitz-Patrick JD. Cost effectiveness of magnetic resonance imaging in neurosciences. BMJ 1991; 303:1435-9.
116. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Cannon T, Gur RC. Phenomenology and functioning in first-episode schizophrenia. Schizophr Bull 1992;18:449-62.
117. Voruganti LN, Awad AG, Oyewumi LK, Cortese L, Zirul S, Dhawan R. Assessing health utilities in schizophrenia. A feasibility study. Pharmacoeconomics 2000; 17:273-86.
118. Herrman H, Hawthorne G, Thomas R. Quality of life assessment in people living with psychosis. Soc Psychiatry Psychiatr Epidemiol 2002; 37:510-18.
119. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307.
120. Lenert LA, Rupnow MF, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes 2005;3:57.
121. Montes JM, Ciudad A, Gascon J, Gomez JC. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Progr Neuropsychopharmacol Biol Psychiatry 2003;27:667-74.
122. Netten A, Curtis L. Unit costs of health and social care 2006. Canterbury: Personal Social Services Research Unit, University of Kent: 2006.
123. British Medical Association/Royal Pharmaceutical Society of Great Britain. British National Formulary. Vol. 53. London: BMA and RPSGB; 2007.
124. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S. A systematic review of typical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7(13).
125. Blomqvist P, Lycke J, Strang P, Törnqvist H, Ekborn A. Brain tumours in Sweden 1996 care and costs. J Neurol Neurosurg Psychiatry 2000;69:792-8.
126. Appleby L. Mental health ten years on: progress on mental health care reform. URL: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyandGuidance/DH074241. Accessed 12 June 2007.
127. British Society of Neuroradiologists. Effective neuroradiology. Guidelines for safe and effective practice. London: British Society of Neuroradiologists; 2003.
128. Gask K. Population review of 2004 and 2005: England and Wales. URL: http://www.statistics.gov.uk/articles/population_trends/ PT126Gask.pdf. Accessed 12 June 2007.
129. Sackett DL, Haynes RB. The architecture of diagnostic research. In Knottnerus JA, editor. The evidence base of clinical diagnosis. London: BMJ Books; 2002. pp. 19-38.
130. Selbie D. Local delivery plans - mental health early intervention services.
131. Mushlin AI, Mooney M, Holloway RG, Detsky AS, Mattson DH, Phelps CE. The cost-effectiveness of magnetic resonance imaging for patients with equivocal neurological symptoms. Int J Technol Assess Health Care 1997;13:21-34.
132. Wortzman G, Holgate RC, Morgan PP. Cranial computed tomograph: an evaluation of cost effectiveness. Radiology 1975;117:75-7.
133. Kulasingam SL, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, McCrory DC. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. Value Health 2003;6:542-50.
134. Law CW, Chen EY, Cheung EF, Chan RC, Wong JG, Lam CL. Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia. Qual Life Res 2005;14:1803-11.
135. Strakowski SM, Johnson JL, DeBello MP, Hamer RM, Green AI, Tohen M. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res 2005; 78:161-9.
136. Malla A, Williams R, Kopala LC, Smith G, Talling D, Balshaw R. Outcome on quality of life in a Canadian national sample of patients with schizophrenia and related psychotic disorders. Acta Psychiatr Scand Suppl 2006;430:22-8.
137. Sciolla A, Patterson TL, Wetherell JL, McAdams LA, Jeste DV. Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with the 36-item short-form (SF-36) health survey. Am J Geriatr Psychiatry 2003;11:629-37.
138. Salyers MP, Bosworth HB, Swanson JW, Lamb-Pagone J, Osher FC. Reliability and validity of the SF-12 health survey among people with severe mental illness. Med Care 2000;38:1141-50.
139. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence based medicine. How to practice and teach EBM. Edinburgh: Churchill Livingstone; 1977.
140. Harris GJ, Lewis RF, Satlin A. Dynamic susceptibility contrast MR imaging or regional cerebral blood volume in Alzheimers disease: a promising alternative to nuclear medicine. Am J Neuroradiol 1998;19:1727-32.
141. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C. The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. Alzheimer Dis Assoc Disord 1997;11:63-70.
142. Puri V, Gupta RK. Magnetic resonance imaging evaluation of focal computed tomography abnormality in epilepsy. Epilepsia 1991; 32:460-6.
143. Convers P, Bierme T, Ryvlin P, Revol M, Fischer C, Froment JC, et al. Contribution of magnetic resonance imaging in 100 cases of refractory partial epilepsy with normal CT scans. Rev Neurol 1990; 146:330-7.
144. Salas-Puig J, Lahoz CH, Mateos V, Guisasola LM, Tunon A. Drug-resistant focal epilepsy with normal cranial CT. Electroclinical correlation and magnetic resonance in 45 patients. Neurologia 1993;8:8-12.
145. Adams C, Hwang PA, Gilday DL, Armstrong DC, Becker LE, Hoffman HJ. Comparison of SPECT, EEG, CT, MRI and pathology in partial epilepsy. Pediatr Neurol 1992;8:97-103.
146. Froment JC, Mauguiere F, Fischer C, Revol M, Bierme T, Convers P. Magnetic resonance imaging in refractory focal epilepsy with normal CT scans. J Neuroradiol 1989;16:285-91.
147. Stefan H, Pawlik G, Bocher-Schwarz HG, Biersack HJ, Burr W, Penin H, et al. Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT, and PET. J Neurol 1987;234: 377-84.
148. Carrilho PG, Yacubian EM, Cukiert A, Fiore LA, Buchpiguel CA, Jorje CL, et al. MRI and brain spect findings in patients with unilateral temporal lobe epilepsy and normal CT scan. Arq Neuropsiquiatr 1994;52:149-52.
149. Baker HL, Houser W, Campbell JK. National Cancer Institute Study: evaluation of computed tomography in the diagnosis of intracranial neoplasms. Radiology 1980;135:91-6.
150. Gray J, Swaiman KF. Brain tumors in children with neurofibromatosis: computed tomography and magnetic resonance imaging. Pediatr Neurol 1987;3:335-41.
151. von Einsiedel G, Loffler W. Nuclear magnetic resonance imaging of brain tumors unrevealed by CT. Eur J Radiol 1982;2:226-34.
152. Guckel C, Benz-Bohm G, Wiedemann G, Thun F. Nuclear magnetic resonance tomographic diagnosis of brain tumours in children and adolescents. A comparison with computed tomography. Rofo Fortschr Geb Rontgenstr Nuklearmed 1990;153:313-20.
153. Suzuki K, Yamamoto M, Hasegawa Y, Ando M, Shima K, Sako C, et al. Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. Lung Cancer 2004; 46:357-60.
154. Nomoto Y, Miyamoto T, Yamaguchi Y. Brain metastasis of small cell lung carcinoma: comparison of Gd-DTPA enhanced magnetic resonance imaging and enhanced computerised tomography. Jpn J Clin Oncol 1994; 24:258-62.
155. Taphoorn NJ, Heimans JJ, Kaiser MC, de Slegte RG, Crezee FC, Valk J. Imaging of brain metastases. Comparison of computerised tomography (CT) and magnetic resonance imaging (MRI). Neuroradiology 1989; 31:391-5.
156. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
157. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9(15).